Important legal notices
Contact   |   Search   

Find your way around the Research site

Menu above created with UDM - used by kind permission of the author


News Alert

Also available in: EN (Other available languages: FR DE )


European scientists develop H7N1 avian flu vaccine

Brussels, 27 October 2005

Supported by the EU Research Framework Programme, influenza experts from the UK, Italy and Norway, working with vaccine researchers from Sanofi Pasteur in France, have developed the first human candidate vaccine for the H7N1 virus. Following this research breakthrough, it is planned that this new vaccine, called ‘RD-3’, will go into clinical trials in Spring 2006. Most vaccine development has centred on H5N1 thus far, which is the highly pathogenic form of the avian influenza (“bird flu”) dominating the news at present. However, a report from the FLUPAN research project in last week’s Journal of Infectious Disease (JID) notes that also the H7 virus can spread from poultry to humans.

The vaccine research project is called FLUPAN and is funded by the European Union to demonstrate European capacity to produce a safe and effective vaccine against highly pathogenic avian influenza viruses. The FLUPAN consortium consists of six partners: Health Protection Agency, UK; Istituto Superiore di Sanita, Italy; National Institute for Biological Standards and Control, UK; Sanofi Pasteur, France, the vaccines business of the Sanofi-Aventis Group; University of Bergen, Norway; University of Reading, UK.

The project began in September 2001 by selecting a highly pathogenic H7N1 virus as a potential pandemic virus. This virus caused lethal outbreaks in Italian poultry in 1999 and was related to the H7N7 poultry virus in the Netherlands.

As the H7N1 virus was too dangerous for direct use in standard influenza vaccine production, it was modified to make it safe using a process called ‘reverse genetics’. The ‘custom-built’ RD-3 vaccine, passed international safety tests and is now being used by Sanofi Pasteur to produce a vaccine. It is the first vaccine not to use eggs in its production by using the reverse genetics technique.

The risk of H7 as emerging as a pandemic influenza strain is considered to be lower than H5N1. Nonetheless, it is expected that the H7 FLUPAN research will be a valuable resource for pandemic vaccine development in the future. The research appears in the October 15 issue (p. 1318) of The Journal of Infectious Diseases, which can be found at

An expert meeting last week in Brussels investigated further research needs in the area of avian and pandemic influenza. The experts concluded that a rapid mobilization of extra-ordinary research efforts is required to address the imminent needs in animal health and the protection of humans from both avian influenza and the potential emergence of pandemic influenza in humans with possible devastating consequences. Therefore, the fight against the disease needs to be tackled at the source, i.e. in animals, while at the same time, a major effort is needed to ensure the protection of humans through the availability of highly performing pandemic influenza vaccines.
For more information on the EU-funded research project FLUPAN:

For further information on avian influenza from World Health Organisation (WHO):

Media Contacts :
Michael H. Wappelhorst, Press and information officer
Information and communication Unit, Research DG, European Commission
Tel: +32.2.298 75 75, Fax: +32.2.295 82 20


Press releases I What's new on the Research pages? I TOP Top